Ojjaara
Term · Oncology and biomedicine · MLC-T-ONC-006037
A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.
| Identifier | MLC-T-ONC-006037 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | momelotinib dihydrochloride monohydrate |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-006037",
"term": "Ojjaara",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.",
"synonyms": [
"momelotinib dihydrochloride monohydrate"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ojjaara/"
}
Record 12,123 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.